 SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 GLOBE NEWSWIRE -- Tempest Therapeutics, Inc. Nasdaq: TPST, a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Dara Burdette, Ph.D., Senior Director of Discovery Research at Tempest, will present on the companys TREX1 pipeline asset and will serve as chairperson for the New Approaches to Solid Tumor Targeting session at the Emerging Technologies for IO Targeting and Discovery Summit taking place October 13-14, 2022 in Boston, MA. 